Leadership
  • Bonnie H. Anderson
    Chief Executive Officer and Chairman of the Board
    • Bonnie H. Anderson is Chief Executive Officer and Chairman of the Board of Veracyte, a pioneering genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in healthcare – enabling patients to get diagnosed sooner and avoid invasive surgeries and other costly procedures. Her career spans over 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in
    • leadership positions atBeckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2015, Fast Company magazine named Ms. Anderson to its “100 Most Creative People in Business” list. She was named one of the “Most Influential Women in Bay Area Business” (2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).
  • John L. Bishop
    • Mr. Bishop began serving as a member of our board of directors in December 2014, and was subsequently appointed Lead Independent Director in December 2016. Mr. Bishop retired at the end of 2016 as chairman and chief executive officer of Cepheid, a leading global molecular diagnostics company, following the acquisition of Cepheid by Danaher in November of 2016. Prior to that, he was president and chief executive officer of Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories. From 1991 until 1993, Mr. Bishop was chairman and chief executive officer of MicroProbe Corporation, a biotechnology company, and from 1987
    • until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. Prior to that, from 1984 to 1986, he was president and chief operating officer of Gen-Probe, Inc., a molecular diagnostics company.  Mr. Bishop served as a director of Conceptus, Inc., a medical device company, from February 2009 until June 2013 when it was acquired by Bayer HealthCare LLC. He also served as a member of the AdvaMedDx Board, a medical diagnostics industry advocacy group, since 2010 — serving as chairman from December 2013 to December 2016.
  • Fred E. Cohen, M.D., D.Phil.
    • Fred E. Cohen, M.D., D.Phil., F.A.C.P., has served as a director since January 2007.  Dr. Cohen is a TPG Partner and Managing Director, having joined TPG in 2001, and serves as co-head of TPG’s biotechnology group.  Dr. Cohen is also a former member of the faculty at the University of California, San Francisco, where he taught and conducted research from 1988 through 2014.  Dr. Cohen also serves as a director of the following public companies:  Genomic Health Inc., a company focused on providing actionable genomic health information; Five Prime Therapeutics, Inc., a clinic-stage biotechnology company focused on discovering and developing novel protein therapeutics; Tandem Diabetics Care, Inc., a medical device company that designs, develops and commercializes products for people with insulin-dependent diabetes; BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the
    • development of novel, small-molecule drugs that block key enzymes involved in infectious and rare diseases; Roka BioScience, Inc., a food safety diagnostics business; and CareDx, Inc., a molecular diagnostics business focused on organ transplant recipients. He is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences.  Dr. Cohen holds a Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biosphysics from Oxford University, where he was a Rhodes Scholar, and an M.D. from Stanford Univeristy.
  • Karin Eastham, M.B.A.
    • Karin Eastham has served as a member our board of directors since December 2012. Ms. Eastham serves on the boards of directors of several life sciences companies. From May 2004 to September 2008, Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research, a non-profit corporation engaged in biomedical research. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a diagnostics company, from 1976 to 1988.
    • Ms. Eastham currently serves as a director of Geron Corporation, Illumina, Inc., and MorphoSys AG. Ms. Eastham served as a director of Amylin Pharmaceuticals, Inc. from September 2005 until its acquisition in August 2012, Genoptix, Inc. from August 2008 until its acquisition in March 2011, Tercica, Inc. from December 2003 until its acquisition in October 2008, and Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant.
  • Robert S. Epstein, M.D., M.S.
    • Robert S. Epstein, M.D., M.S., is a strategic consultant to life sciences companies and an epidemiologist with extensive expertise in pharmacoeconomics and health outcomes research, having held various positions in academia and public health before joining the private sector. From 2010 to 2012, Dr. Epstein served as president of the Medco-UBC Division and as chief research and development officer of Medco Health Solutions, Inc., a managed healthcare company that covered 65 million people. In these roles, Dr. Epstein was responsible for all of Medco’s clinical research initiatives, including the Medco Research Consortium (“Medco”) and United BioSource Corporation. Dr. Epstein served as Medco’s chief medical officer from 1997 to 2010, leading formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting.
    • Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and served on the Board of Directors of the Drug Information Association (DIA) and the International Society of Quality of Life. He has also served on the federal CDC EGAPP (Evaluation of Genomic Applications in Practice & Prevention) Stakeholder Committee and the AHRQ CERTs (Centers for Education and Research on Therapeutics) Committee. In addition to Veracyte, Dr. Epstein serves on the Board of Directors of Illumina, Inc., Proteus Digital Health, Inc. and Fate Therapeutics, Inc.
  • Kevin K. Gordon
    • Kevin K. Gordon joined the Veracyte board in December 2016. Mr. Gordon served as executive vice president and COO of Quintiles, a leading global bio-pharmaceutical services provider, from October 2015 until its merger with IMS Health in October 2016. He served as the company’s executive vice president and chief financial officer from July 2010 to December 2015. The Fortune 500 company recorded revenue of $4.3 billion in 2015 and was named to Fortune’s list of the “World’s Most Admired Companies.” Prior to that, Mr.
    • Gordon spent 13 years in senior leadership positions at Teleflex Incorporated (NYSE: TFX), a diversified global company with over $2 billion in annual revenue, where he served as executive vice president and CFO from March 2007 to January 2010. He previously held senior management positions at KPMG. Mr. Gordon served as chairman of the board of SSI Surgical Services, Inc. He holds a B.S. in Accounting from the University of Connecticut.
  • Evan Jones, M.B.A.
    • Evan Jones has served as a member of our board of directors since February 2008. Mr. Jones has served since 2007 as Managing Member of jVen Capital, LLC, a life sciences investment company. He also serves as executive chairman of Opgen, Inc., a privately held genetic analysis company. He was a co-founder of Digene Corporation, a publicly-traded biotechnology company focused on women's health and molecular diagnostic testing, serving as Chairman of the Board from 1995 until its acquisition in 2007
    • and serving as Chief Executive Officer from 1990 to 2006 and as President from 1990 to 1999. Mr. Jones is a director of CAS Medical Systems, Inc., Fluidigm Corporation and Foundation Medicine, Inc. Mr. Jones received a B.A. in Biotechnology from the University of Colorado and an M.B.A. from The Wharton School at the University of Pennsylvania.
  • Tina S. Nova, Ph.D.
    • Tina S. Nova, Ph.D., began serving as a member of our board of directors in November 2015. Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manager of Illumina’s oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation for
    • nearly $0.5 billion in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and is vice chairman of the board of directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children’s Hospital-San Diego. She holds a B.S. degree in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.
  • Jesse Treu, Ph.D.
    • Jesse Treu, Ph.D., has served as a member our board of directors since June 2010. Dr. Treu has been a partner of Domain since its inception in 1985. He has been a director of 37 early-stage healthcare companies, 23 of which have so far become successful public companies. Present board memberships include Afferent Pharmaceuticals, Aldeyra Therapeutics, CoLucid Pharmaceuticals, RightCare Solutions, Inc., Sebacia, Inc., Tandem Diabetes Care, Veracyte and Xagenic, Inc. He has served as a founder, president and chairman of numerous venture stage companies. Prior to
    • the formation of Domain, Dr. Treu was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as president and CEO of Microsonics, a pioneer in computer image processing for cardiology. Previous to that, Dr. Treu held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics) and at GE. He received his B.S. in physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University.